CXCL12 and neoplasm: Preclinical work shows that NPs mediated modulation of bone marrow cytokines (e.g., IL-6, CXCL12) improves CAR-T infiltration and cytotoxicity, resulting in 40–60% superior tumor clearance compared with CAR-T alone in animal models [82,121].